Polyglutamine aggregation in huntington and related diseases

Advances in Experimental Medicine and Biology

Volumn 769, Issue , 2012, Pages 125-140

  Polling, Saskia ^a   Hill, Andrew F ^a   Hatters, Danny M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE;

BETA SHEET; CELL INCLUSION; CELLULAR DISTRIBUTION; CYTOTOXICITY; HUMAN; HUNTINGTON CHOREA; MACROAUTOPHAGY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN STRUCTURE; REVIEW; UNFOLDED PROTEIN RESPONSE; CHAPERONE-MEDIATED AUTOPHAGY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GAIN OF FUNCTION MUTATION; LOSS OF FUNCTION MUTATION; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN HOMEOSTASIS; TRINUCLEOTIDE REPEAT;

EID: 84934444551     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5434-2_8     Document Type: Review

References (181)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group. Cell 1993; 72(6):971-983.
2. Orr HT, Chung MY, Banfi S et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993; 4(3):221-226.
3. Imbert G, Saudou F, Yvert G et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996; 14(3):285-291.
4. Sanpei K, Takano H, Igarashi S et al. Identification of the spinocerebellar ataxiatype 2 gene using a direct identification of repeat expansion and cloningtechnique, DIRECT. Nat Genet 1996; 14(3):277-284.
5. Kawaguchi Y, Okamoto T, Taniwaki M et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8(3):221-228.
6. Zhuchenko O, Bailey J, Bonnen P et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997; 15(1):62-69.
7. David G, Abbas N, Stevanin G et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997; 17(1):65-70.
8. Nakamura K, Jeong SY, Uchihara T et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001; 10(14):1441-1448.
9. Andrew SE, Goldberg YP, Kremer B et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993; 4(4):398-403.
10. La Spada AR, Wilson EM, Lubahn DB et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352(6330):77-79.
11. Koide R, Ikeuchi T, Onodera O et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994; 6(1):9-13.
12. Nagafuchi S, Yanagisawa H, Ohsaki E et al. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet 1994; 8(2):177-182.
13. Koshy BT, Zoghbi HY. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Brain Pathol 1997; 7(3):927-942.
14. Scherzinger E, Lurz R, Turmaine M et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90(3):549-558.
15. Scherzinger E, Sittler A, Schweiger K et al. Self-assembly ofpolyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci U S A 1999; 96(8):4604-4609.
16. Caputo CB, Fraser PE, Sobel IE et al. Amyloid-like properties of a synthetic peptide corresponding to the carboxy terminus of beta-amyloid protein precursor. Arch Biochem Biophys 1992; 292(1):199-205.
17. Prusiner SB, McKinley MP, Bowman KA et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983; 35(2 Pt 1):349-358.
18. Huang CC, Faber PW, Persichetti F et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 1998; 24(4):217-233.
19. Ferrone F. Analysis of protein aggregation kinetics. Methods Enzymol 1999; 309:256-274.
20. Berthelier V, Hamilton JB, Chen S et al. A microtiter plate assay for polyglutamine aggregate extension. Anal Biochem 2001; 295(2):227-236.
21. Esler WP, Stimson ER, Jennings JM et al. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 2000; 39(21):6288-6295.
22. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993; 73(6):1055-1058.
23. Chen S, Ferrone FA, Wetzel R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A 2002; 99(18):11884-11889.
24. Bernacki JP, Murphy RM. Model discrimination and mechanistic interpretation of kinetic data in protein aggregation studies. Biophys J 2009; 96(7):2871-2887.
25. Walters RH, Murphy RM. Examining polyglutamine peptide length: a connection between collapsed conformations and increased aggregation. J Mol Biol 2009; 393(4):978-992.
26. Lee CC, Walters RH, Murphy RM. Reconsidering the mechanism of polyglutamine peptide aggregation. Biochemistry 2007; 46(44):12810-12820.
27. Legleiter J, Mitchell E, Lotz GP et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 2010; 285(19):14777-14790.
28. Wacker JL, Zareie MH, Fong H et al. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol 2004; 11(12):1215-1222.
29. Bhattacharyya AM, Thakur AK, Wetzel R. polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc Natl Acad Sci U S A 2005; 102(43):15400-15405.
30. Dougan L, Li J, Badilla CL et al. Single homopolypeptide chains collapse into mechanically rigid conformations. Proc Natl Acad Sci U S A 2009; 106(31):12605-12610.
31. Wang X, Vitalis A, Wyczalkowski MA et al. Characterizing the conformational ensemble of monomeric polyglutamine. Proteins 2006; 63(2):297-311.
32. Crick SL, Jayaraman M, Frieden C et al. Fluorescence correlation spectroscopy shows that monomeric polyglutamine molecules form collapsed structures in aqueous solutions. Proc Natl Acad Sci U S A 2006; 103(45):16764-16769.
33. Altschuler EL, Hud NV, Mazrimas JA et al. Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res 1997; 50(1):73-75.
34. Chen S, Berthelier V, Yang W et al. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 2001; 311(1):173-182.
35. Masino L, Kelly G, Leonard K et al. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett 2002; 513(2-3):267-272.
36. Vitalis A, Wang X, Pappu RV. Atomistic simulations ofthe effects ofpolyglutamine chain length and solvent quality on conformational equilibria and spontaneous homodimerization. J Mol Biol 2008; 384(1):279-297.
37. Pappu RV, Wang X, Vitalis A et al. A polymer physics perspective on driving forces and mechanisms for protein aggregation. Arch Biochem Biophys 2008; 469(1):132-141.
38. Venkatraman P, Wetzel R, Tanaka M et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004; 14(1):95-104.
39. Poirier MA, Li H, Macosko J et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 2002; 277(43):41032-41037.
40. Chen S, Berthelier V, Hamilton JB et al. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 2002; 41(23):7391-7399.
41. Vitalis A, Lyle N, Pappu RV. Thermodynamics of beta-sheet formation in polyglutamine. Biophys J 2009; 97(1):303-311.
42. Bhattacharyya A, Thakur AK, Chellgren VM et al. Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol 2006; 355(3):524-535.
43. Nekooki-Machida Y, Kurosawa M, Nukina N et al. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci U S A 2009; 106(24):9679-9684.
44. Bevivino AE, Loll PJ. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils. Proc Natl Acad SciUSA 2001; 98(21):11955-11960.
45. Perutz MF, Finch JT, Berriman J et al. Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci USA 2002; 99(8):5591-5595.
46. Singer SJ, Dewji NN. Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc Natl Acad Sci U S A 2006; 103(5):1546-1550.
47. Perutz MF, Johnson T, Suzuki M et al. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 1994; 91(12):5355-5358.
48. Sharma D, Shinchuk LM, Inouye H et al. Polyglutamine homopolymers having 8-45 residues form slablike beta-crystallite assemblies. Proteins 2005; 61(2):398-411.
49. Tanaka M, Morishima I, Akagi T et al. Intra- and intermolecular beta-pleated sheet formation in glutamine-rep eat inserted myoglobin as a model for polyglutamine diseases. J Biol Chem 2001; 276(48):45470-45475.
50. Sikorski P, Atkins E. New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules 2005; 6(l):425-432.
51. Thakur AK, Wetzel R. Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci U S A 2002; 99(26):17014-17019.
52. Makin OS, Atkins E, Sikorski P et al. Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci U S A 2005; 102(2):315-320.
53. DiFiglia M, Sapp E, Chase KO et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277(5334):1990-1993.
54. Davies SW, Turmaine M, Cozens BA et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90(3):537-548.
55. Lunkes A, Trottier Y, Mandel JL. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases. Essays Biochem 1998; 33:149-163.
56. Olshina MA, Angley LM, Ramdzan YM et al. Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem 2010; 285(28):21807-21816.
57. Ramdzan YM, Nisbet RM, Miller J et al. Conformation sensors that distinguish monomeric proteins from oligomers in live cells. Chem Biol 2010; 17(4):371-379.
58. Ossato G, Digman MA, Aiken C et al. A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. Biophys J 2010; 98(12):3078-3085.
59. Muchowski PJ, Ning K, D'Souza-Schorey C et al. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci U S A 2002; 99(2):727-732.
60. Taylor JP, Tanaka F, Robitschek J et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 2003; 12(7):749-757.
61. Mitra S, Tsvetkov AS, Finkbeiner S. Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in Huntington disease. J Biol Chem 2009; 284(7):4398-4403.
62. Ortega Z, Diaz-Hernandez M, Maynard CJ et al. Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci 2010; 30(10):3675-3688.
63. Arrasate M, Mitra S, Schweitzer ES et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431(7010):805-810.
64. Kaganovich D, Kopito R, Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature 2008; 454(7208):1088-1095.
65. Johnston JA, Illing ME, Kopito RR. Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 2002; 53(1):26-38.
66. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143(7):1883-1898.
67. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10(12):524-530.
68. Garcia-Mata R, Bebok Z, Sorscher EJ et al. Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 1999; 146(6):1239-1254.
69. Waelter S, Boeddrich A, Lurz R et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001; 12(5):1393-1407.
70. Wang H, Strandin T, Hepojoki J et al. Degradation and aggresome formation ofthe Gn tail ofthe apathogenic Tula hantavirus. J Gen Virol 2009; 90(Pt 12):2995-3001.
71. Stenoien DL, Mielke M, Mancini MA. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat Cell Biol 2002; 4(10):806-810.
72. DiFiglia M, Sapp E, Chase KO et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277(5334):1990-1993.
73. Eriguchi M, Mizuta H, Luo S et al. Alpha Pix enhances mutant huntingtin aggregation. J Neurol Sci 2010; 290(1-2):80-85.
74. Shao J, Welch WJ, Diprospero NA et al. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 2008; 28(17):5196-5208.
75. Burnett BG, Andrews J, Ranganathan S et al. Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamics. Neurobiol Dis 2008; 30(3):365-374.
76. Angeli S, Shao J, Diamond MI. F-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristics. PLoS One 2010; 5(2):e9053.
77. Kim YJ, Yi Y, Sapp E et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci U S A 2001; 98(22):12784-12789.
78. Landles C, Sathasivam K, Weiss A et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 2010; 285(12):8808-8823.
79. Li X, Li H, Li XJ. Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Res Rev 2008; 59(1):245-252.
80. Sieradzan KA, Mechan AO, Jones L et al. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999; 156(1):92-99.
81. Martindale D, Hackam A, Wieczorek A et al. Length ofhuntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998; 18(2):150-154.
82. Hackam AS, SingarajaR, Wellington CL etal. The influence ofhuntingtin protein size onnuclear localization and cellular toxicity. J Cell Biol 1998; 141(5):1097-1105.
83. Warby SC, Doty CN, Graham RK et al. Activated caspase-6 and caspase-6-cleaved fragments ofhuntingtin specifically colocalize inthe nucleus. Hum Mol Genet 2008; 17(15):2390-2404.
84. Graham RK, Deng Y, Slow EJ et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125(6):1179-1191.
85. Schilling B, Gafni J, Torcassi C et al. Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 2006; 281(33):23686-23697.
86. Aiken CT, Steffan JS, Guerrero CM et al. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 2009; 284(43):29427-29436.
87. Rockabrand E, Slepko N, Pantalone A et al. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 2007; 16(1):61-77.
88. Steffan JS, AgrawalN, Pallos Jet al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004; 304(5667):100-104.
89. Yanai A, Huang K, Kang R et al. Palmitoylation ofhuntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci 2006; 9(6):824-831.
90. Jeong H, Then F, Melia TJ Jr et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009; 137(1):60-72.
91. Humbert S, Bryson EA, Cordelieres FP et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002; 2(6):831-837.
92. Rangone H, Poizat G, Troncoso J et al. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 2004; 19(2):273-279.
93. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90(3):905-981.
94. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004; 20(3):146-154.
95. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000; 23:217-247.
96. Marsh JL, Walker H, Theisen H et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000; 9(1):13-25.
97. Zeitlin S, Liu JP, Chapman DL et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11(2):155-163.
98. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000; 26(3):300-306.
99. Leavitt BR, Guttman JA, Hodgson JG et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 2001; 68(2):313-324.
100. Van Raamsdonk JM, Pearson J, Murphy Z et al. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci 2006; 7:80.
101. Leavitt BR, van Raamsdonk JM, Shehadeh J et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 2006; 96(4):1121-1129.
102. Ho LW, Brown R, Maxwell M et al. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. J Med Genet 2001; 38(7):450-452.
103. Busch A, Engemann S, Lurz R et al. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J Biol Chem 2003; 278(42):41452-41461.
104. Perez MK, Paulson HL, Pendse SJ et al. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol 1998; 143(6):1457-1470.
105. Kazantsev A, Preisinger E, Dranovsky A et al. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci U S A 1999; 96(20):11404-11409.
106. Steffan JS, Kazantsev A, Spasic-Boskovic O et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000; 97(12):6763-6768.
107. Holbert S, Denghien I, Kiechle T et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci U S A 2001; 98(4):1811-1816.
108. Chai Y, Wu L, Griffin JD et al. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem 2001; 276(48):44889-44897.
109. Kim S, Nollen EA, Kitagawa K et al. Polyglutamine protein aggregates are dynamic. Nat Cell Biol 2002; 4(10):826-831.
110. Gidalevitz T, Ben-Zvi A, Ho KH et al. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006; 311(5766):1471-1474.
111. Prahlad V, Morimoto RI. Integrating the stress response: lessons for neurodegenerative diseases from C. elegans. Trends Cell Biol 2009; 19(2):52-61.
112. Cornett J, Cao F, Wang CE et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 2005; 37(2):198-204.
113. Lee WC, Yoshihara M, Littleton JT. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 2004; 101(9):3224-3229.
114. Milnerwood AJ, Raymond LA. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol 2007; 585(Pt 3):817-831.
115. Schaffar G, Breuer P, Boteva R et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 2004; 15(1):95-105.
116. Piccioni F, Pinton P, Simeoni S et al. Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motor neuronal processes. FASEB J 2002; 16(11):1418-1420.
117. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003; 28(8):425-433.
118. Strehlow AN, Li JZ, Myers RM. Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space. Hum Mol Genet 2007; 16(4):391-409.
119. Monoi H, Futaki S, Kugimiya S et al. Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys J 2000; 78(6):2892-2899.
120. Suopanki J, Gotz C, Lutsch G et al. Interaction of huntingtin fragments with brain membranes - clues to early dysfunction in Huntington's disease. J Neurochem 2006; 96(3):870-884.
121. Ren P-H, Lauckner JE, Kachirskaia I et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11(2):219-225.
122. Kegel KB, Sapp E, Alexander J et al. Polyglutamine expansion in huntingtin alters its interaction with phospholipids. J Neurochem 2009; 110(5):1585-1597.
123. Kegel KB, Schewkunow V, Sapp E et al. Polyglutamine expansion in huntingtin increases its insertion into lipid bilayers. Biochem Biophys Res Commun 2009; 387(3):472-475.
124. Lashuel HA, Petre BM, Wall J et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular andtubular protofibrils. J Mol Biol 2002; 322(5):1089-1102.
125. Brignull HR, Morley JF, Garcia SM et al. Modeling polyglutamine pathogenesis in C. elegans. Methods Enzymol 2006; 412:256-282.
126. Diguet E, Petit F, Escartin C et al. Normal aging modulates the neurotoxicity of mutant huntingtin. PLoS One 2009; 4(2):e4637.
127. David DC, Ollikainen N, Trinidad JC et al. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol 2010; 8(8):e1000450.
128. Tonkiss J, Calderwood SK. Regulation ofheat shock gene transcription in neuronal cells. Int J Hyperthermia 2005; 21(5):433-444.
129. Cuervo AM, Dice JF. Regulation of lamp2a levels in the lysosomal membrane. Traffic 2000; l(7):570-583.
130. DuennwaldML, Lindquist S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev 2008; 22(23):3308-3319.
131. Jana NR, Zemskov EA, Wang G et al. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001; 10(10):1049-1059.
132. Sarkar S, Rubinsztein DC. Huntington's disease: degradation of mutant huntingtin by autophagy. FEBS J 2008; 275(17):4263-4270.
133. Li X, Wang CE, Huang S et al. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. Hum Mol Genet 2010; 19(12):2445-2455.
134. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003; 40(2):427-446.
135. Abel A, Walcott J, Woods J et al. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum Mol Genet 2001; 10(2):107-116.
136. Stenoien DL, Cummings CJ, Adams HP et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components, and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet 1999; 8(5):731-741.
137. Mitsui K, Nakayama H, Akagi T et al. Purification of polyglutamine aggregates and identification of elongation factor-1alpha and heat shock protein 84 as aggregate-interacting proteins. J Neurosci 2002; 22(21):9267-9277.
138. Khan LA, Bauer PO, Miyazaki H et al. Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. J Neurochem 2006; 98(2):576-587.
139. Bowman AB, Yoo SY, Dantuma NP et al. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 2005; 14(5):679-691.
140. Bett JS, Cook C, Petrucelli L et al. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. PLoS One 2009; 4(4):e5128.
141. Wang J, Wang CE, Orr A et al. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol 2008; 180(6):1177-1189.
142. Warrick JM, Chan HY, Gray-Board GL et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999; 23(4):425-428.
143. Chai Y, Koppenhafer SL, Bonini NM et al. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci 1999; 19(23):10338-10347.
144. Lotz GP, Legleiter J, Aron R et al. Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem 2010.
145. Behrends C, Langer CA, Boteva R et al. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 2006; 23(6):887-897.
146. Heng MY, Detloff PJ, Paulson HL et al. Early alterations of autophagy in Huntington disease-like mice. Autophagy 2010; 6(8):1206-1208.
147. Tung YT, Hsu WM, Lee H et al. The evolutionarily conserved interaction between LC3 and p62 selectively mediates autophagy-dependent degradation ofmutant huntingtin. Cell Mol Neurobiol 2010; 30(5):795-806.
148. Martinez-Vicente M, Talloczy Z, Wong E et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010; 13(5):567-576.
149. Ravikumar B, Vacher C, Berger Z et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36(6):585-595.
150. Hara T, Nakamura K, Matsui M et al. Suppression ofbasal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441(7095):885-889.
151. Komatsu M, Waguri S, Chiba T et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441(7095):880-884.
152. Metzger S, Saukko M, Van Che H et al. Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. Hum Genet 2010; 128(4):453-459.
153. Kegel KB, Kim M, Sapp E et al. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 2000; 20(19):7268-7278.
154. Sapp E, Schwarz C, Chase K et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997; 42(4):604-612.
155. Yamada M, Tsuji S, Takahashi H. Pathology ofCAG repeat diseases. Neuropathology 2000; 20(4):319-325.
156. Yamada M, Tsuji S, Takahashi H. Involvement of lysosomes in the pathogenesis of CAG repeat diseases. Ann Neurol 2002; 52(4):498-503.
157. Thompson LM, Aiken CT, Kaltenbach LS et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009; 187(7):1083-1099.
158. Cuervo AM, Stefanis L, Fredenburg R et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004; 305(5688):1292-1295.
159. Li LB, Yu Z, Teng X et al. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 2008; 453(7198):1107-1111.
160. Mankodi A, Logigian E, Callahan L et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000; 289(5485):1769-1773.
161. Amack JD, Paguio AP, Mahadevan MS. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum Mol Genet 1999; 8(11):1975-1984.
162. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29(1):40-47.
163. Mankodi A, Takahashi MP, Jiang H et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002; 10(1):35-44.
164. Taneja KL, McCurrach M, Schalling M et al. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 1995; 128(6):995-1002.
165. Liquori CL, Ricker K, Moseley ML et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293(5531):864-867.
166. Koob MD, Moseley ML, Schut LJ et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet 1999; 21(4):379-384.
167. Buraczynska MJ, Van Keuren ML, Buraczynska KM et al. Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis. Cytogenet Cell Genet 1995; 71(2):197-202.
168. Sathasivam K, Hobbs C, Turmaine M et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8(5):813-822.
169. Bradford JW, Li S, Li XJ. Polyglutamine toxicity in non-neuronal cells. Cell Res 2010; 20(4):400-407.
170. Ribchester RR, Thomson D, Wood NI et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 2004; 20(11):3092-3114.
171. Andreassen OA, Dedeoglu A, Stanojevic V et al. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 2002; 11(3): 410-424.
172. Mihm MJ, Amann DM, Schanbacher BL et al. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 25(2):297-308.
173. Hurlbert MS, Zhou W, Wasmeier C et al. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 1999; 48(3):649-651.
174. MoffittH, McPhail GD, Woodman B et al. Formation of polyglutamine inclusions inawiderange ofnon-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 2009; 4(11):e8025.
175. Fuentealba LC, Eivers E, Geissert D et al. Asymmetric mitosis: unequal segregation of proteins destined for degradation. Proc Natl Acad Sci U S A 2008; 105(22):7732-7737.
176. Rujano MA, Bosveld F, Salomons FA et al. Polarised asymmetric inheritance of accumulated protein damage in higher eukaryotes. PLoS Biol 2006; 4(12):e417.
177. Morley JF, Brignull HR, Weyers JJ et al. The threshold for polyglutamine-expansion protein aggregation and cellulartoxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A 2002; 99(16):10417-10422.
178. Hobbs NZ, Barnes J, Frost C et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010; 31(6):1036-1041.
179. Nopoulos PC, Aylward EH, Ross CA et al. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain 2010.
180. Molero AE, Gokhan S, Gonzalez S et al. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc Natl Acad Sci U S A 2009; 106(51):21900-21905.
181. Powers ET, Morimoto RI, Dillin A et al. Biological and chemical approaches to diseases of proteostasis deficiency. Ann Rev Biochem 2009; 78(1):959-991.